ALKEM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | ALKEM | Market Cap | 64,178 Cr. | Current Price | 5,374 ₹ | High / Low | 5,934 ₹ |
| Stock P/E | 27.9 | Book Value | 1,171 ₹ | Dividend Yield | 0.84 % | ROCE | 19.9 % |
| ROE | 17.5 % | Face Value | 2.00 ₹ | DMA 50 | 5,401 ₹ | DMA 200 | 5,432 ₹ |
| Chg in FII Hold | 0.18 % | Chg in DII Hold | -0.15 % | PAT Qtr | 294 Cr. | PAT Prev Qtr | 654 Cr. |
| RSI | 50.3 | MACD | -21.8 | Volume | 87,472 | Avg Vol 1Wk | 77,725 |
| Low price | 4,716 ₹ | High price | 5,934 ₹ | PEG Ratio | 1.06 | Debt to equity | 0.04 |
| 52w Index | 54.0 % | Qtr Profit Var | 30.2 % | EPS | 191 ₹ | Industry PE | 32.5 |
📊 ALKEM demonstrates strong fundamentals for long-term investment. With ROE (17.5%) and ROCE (19.9%), the company shows good capital efficiency. Debt-to-equity is very low (0.04), ensuring financial stability. The P/E ratio (27.9) is below the industry average (32.5), suggesting fair valuation. The PEG ratio (1.06) indicates balanced growth prospects. Dividend yield (0.84%) provides modest passive income. However, quarterly PAT declined from 654 Cr. to 294 Cr., which requires monitoring. EPS (191 ₹) remains strong, supporting long-term sustainability.
💡 Entry Price Zone: A favorable entry would be between 5,000 ₹ – 5,300 ₹, closer to DMA 50 (5,401 ₹) and DMA 200 (5,432 ₹), where valuations align better with long-term growth potential.
📈 Exit Strategy / Holding Period: If already holding, consider a 3–5 year horizon given strong fundamentals. Partial profit booking may be considered near 5,800–6,000 ₹ if valuations remain stretched. Exit only if earnings growth slows further or if P/E expands without EPS support.
🌟 Positive
- Strong [ROE](ca://s?q=Explain_ROE) of 17.5% and [ROCE](ca://s?q=Explain_ROCE) of 19.9% show good capital efficiency.
- Low [debt-to-equity](ca://s?q=Debt_to_equity_explained) ratio of 0.04 ensures financial stability.
- [P/E ratio](ca://s?q=Explain_P/E_ratio) of 27.9 is below industry average (32.5), suggesting fair valuation.
- [PEG ratio](ca://s?q=PEG_ratio_explained) of 1.06 indicates balanced growth prospects.
- Dividend yield of 0.84% provides modest passive income.
- EPS of 191 ₹ supports long-term earnings visibility.
⚠️ Limitation
- Quarterly PAT declined from 654 Cr. to 294 Cr., showing earnings pressure.
- DII holdings decreased by 0.15%, reflecting reduced domestic institutional interest.
- Stock trading at ~54% of 52-week index, indicating moderate price momentum.
📰 Company Negative News
- Quarterly profit decline raises concerns about earnings momentum.
- Muted institutional activity with DII reduction.
📢 Company Positive News
- Strong EPS of 191 ₹ supports long-term sustainability.
- Debt-free structure enhances financial resilience.
- Dividend yield of 0.84% adds investor appeal.
- FII holdings increased slightly (+0.18%), showing foreign investor confidence.
🏭 Industry
- Industry P/E at 32.5, higher than company’s 27.9, showing sector-wide premium valuations.
- Pharmaceutical sector growth driven by global demand, innovation, and healthcare expansion.
✅ Conclusion
ALKEM is fundamentally strong with good ROE, ROCE, and low debt, making it a solid candidate for long-term investment. Entry is ideal near 5,000–5,300 ₹. Long-term investors may hold for 3–5 years, while existing holders can consider partial profit booking near 5,800–6,000 ₹ if valuations remain stretched. Monitoring quarterly earnings will be crucial for sustained returns.